FDA cấp trạng thái đột phá cho thiết bị mạch máu của Efemoral

FDA cấp trạng thái đột phá cho thiết bị mạch máu của Efemoral

Dấu thời gian: ngày 15 tháng 2024 năm 3 50:XNUMX sáng
Nút nguồn: 2481374

The device works by addressing the specific anatomic challenges, as well as complex biomechanics of individuals living with athero-occlusive disease in the leg. Credit: Valerio Pardi / Shutterstock.com.

The US Food and Drug Administration (FDA) has granted breakthrough device status to Efemoral Medical’s Efemoral vascular scaffold system (EVSS).

This designation is intended for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in CLTI patients.

The EVSS represents a new approach to the treatment of peripheral arterial occlusive disease (PAOD), particularly in the infrapopliteal arteries.

It works by addressing the specific anatomic challenges as well as complex biomechanics of individuals living with athero-occlusive disease in the leg.

Efemoral Medical co-founder and CEO Christopher Haig said: “PAOD has a significant negative impact on the health of as many as 20 million Americans.

“It is especially devastating for those 10% of patients suffering from its most severe form, CLTI.  We are extremely gratified that the FDA has recognised the potential of the EVSS to benefit these patients by granting breakthrough device status to our device.”

Truy cập Hồ sơ Công ty toàn diện nhất trên thị trường, được cung cấp bởi GlobalData. Tiết kiệm thời gian nghiên cứu. Đạt được lợi thế cạnh tranh.

Hồ sơ công ty – mẫu miễn phí

Email tải xuống của bạn sẽ sớm đến

Chúng tôi tự tin về chất lượng độc đáo của Hồ sơ Công ty của chúng tôi. Tuy nhiên, chúng tôi muốn bạn đưa ra quyết định có lợi nhất cho doanh nghiệp của mình, vì vậy chúng tôi cung cấp mẫu miễn phí mà bạn có thể tải xuống bằng cách gửi biểu mẫu bên dưới

Bởi GlobalData

The system utilises FlexStep Technology, which combines flexibility and support using serial, intravascular scaffolds to alleviate vessel blockages and maintain optimal blood flow, even amidst vessel bends and bodily movement.

These bioresorbable scaffolds, infused with sirolimus for anti-proliferative effects, not only reinstate the vessel’s natural diameter during the procedure but also provide therapeutic advantages across diverse lesion types and lengths.

The above-the-knee version of the device is currently undergoing a first-in-human trial, EFEMORAL I, in New Zealand and Australian sites.

Early results have been promising, prompting the development of an additional device for below-the-knee artery treatment in CLTI patients.

Efemoral Medical co-founder and CMO Lewis Schwartz said: “Diseased human arteries are most simply, reliably, and successfully treated with drug-eluting, balloon-expandable stents.

“However, it is extremely challenging to implant these permanent devices in the long and twisting arteries of the lower extremities. The EVSS uses a unique design of alternating, dissolvable, drug-eluting scaffolds that, for the first time, allows the long arteries of the legs to be treated with the same, effective, drug-eluting technology proven to be successful in multiple other vascular beds.”

Efemoral Medical released EP3522837, a method of manufacturing a radially rigid and longitudinally flexible multi-element intravascular stent, marking its tenth-issued patent across several different patent families.

Dấu thời gian:

Thêm từ Mạng thiết bị y tế